Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.
about
Particle-mediated delivery of cytokines for immunotherapySimian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cellsGM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicityEnhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination.Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration.Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.Biomaterial Strategies for Immunomodulation.Multiple vaccinations: friend or foe.Biomimetic delivery with micro- and nanoparticlesChitosan solution enhances the immunoadjuvant properties of GM-CSF.Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.Granulocyte-macrophage colony-stimulating factor induces the differentiation of murine erythroleukaemia cells into dendritic cells.Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model.
P2860
Q26997993-DDFB6BA3-AF08-48A0-B5C5-2A5EBF324498Q33848587-475D23EB-B30B-429D-808F-4B806B74EF09Q34364483-9AD99F18-740E-43C9-88D2-9E272B7D6C79Q34975671-A3FFB386-2A33-42F1-B167-341135046164Q35203752-3C59640A-4580-4E43-B58F-F85997151B60Q35922239-DE083D82-FC0F-4DC7-9D69-ABDA5A7C1252Q36081142-6AA5F127-2B4C-4043-94F7-9E7A7970A6C4Q36621492-ED0151D3-064E-43F8-9943-D0D64FE92281Q36703124-5DA6A2C5-60B2-4A98-921F-3F90851B6487Q36734688-044D1A34-DB68-4584-A2C9-FC1217C8524FQ36768786-5508D905-A24F-4E2A-903D-974228B786ACQ36868870-C7355027-DDD1-4F75-AFA2-9AFC7BAA7784Q37305644-057F42A7-3CA6-422B-8587-AB990AD32F95Q40197046-0BA8C4B8-2716-4D0C-805B-0BD1F317A099Q41003634-43585BD8-78A2-4B50-BCED-0DF770F6C989Q42183011-E12F14A2-A028-40B1-9D2F-EDEFCA95778E
P2860
Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Controlled release, biodegrada ...... oach in cancer vaccine design.
@en
type
label
Controlled release, biodegrada ...... oach in cancer vaccine design.
@en
prefLabel
Controlled release, biodegrada ...... oach in cancer vaccine design.
@en
P2093
P1433
P1476
Controlled release, biodegrada ...... oach in cancer vaccine design.
@en
P2093
Golumbek PT
Levitsky HI
Pardoll DM
P304
P407
P577
1993-12-01T00:00:00Z